Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + MAP Chemotherapy for Newly Diagnosed Osteosarcoma
NCT05691478Phase 3Suspended
- Sponsor
- National Cancer Institute
- Start
- Mar 2023
- Primary completion
- Mar 2030
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of cabozantinib in osteosarcoma (OS) (5 arms), sponsored by National Cancer Institute. Primary endpoints: Dose-Limiting Toxicity at 6 weeks, Event-Free Survival at 5 years and 1 more. Started Mar 2023; status: suspended.
02
Drugs
cabozantinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05691478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691478.